Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1

Detalhes bibliográficos
Autor(a) principal: Silva, Igor Barbosa
Data de Publicação: 2013
Outros Autores: Mattos, Katherine Antunes, Dick, Paulo Cesar, Almeida, Alessandra Santos, Silva, Ricardo Gonçalves, Hokama, Darcy Akemi, Paumgartten, Francisco José Roma
Tipo de documento: Artigo
Idioma: por
Título da fonte: Vigilância Sanitária em Debate
Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89
Resumo: In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves).
id FIOCRUZ-9_9ea7fd1f5388f8747b0fc6a2771cb4b1
oai_identifier_str oai:ojs.visaemdebate.incqs.fiocruz.br:article/89
network_acronym_str FIOCRUZ-9
network_name_str Vigilância Sanitária em Debate
repository_id_str
spelling Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1Ensaio de potência da alfaepoetina: Comparação de camundongos Swiss Webster, NIH, C57BL6, BALB/c com o híbrido B6D2F1epoetin alphaPotency assaybioassaymouse strainshuman erythropoietin recombinant (rhEPO)Alfaepoetinaensaio de potênciabioensaiolinhagens de camundongoseritropoietina recombiante humana (EPOhr)In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves).Neste estudo comparamos ensaios de potência da alfaepoetina realizados com camundongos de diferentes colônias e linhagens (Swiss Webster, NIH, C57BL6, BALB/c e híbrido B6D2F1). Os testes foram efetuados com fêmeas pesando 16-18 gramas, tratadas com dose única de alfaepoetina por via subcutânea (30, 90 e 270 UI/ animal). O sangue foi coletado 96 horas após a injeção (72 horas no caso de camundongos SwissWebster). A contagem dos reticulócitos foi realizada em câmara de Neubauer. Apresentações de 4000 UI/mL foram avaliadas utilizando um material de referência de trabalho de alfaepoetina (3773 UI/mL) anteriormente testado frente ao padrão de referência internacional BRP (European Pharmacopeia Biological Reference Preparation). Os resultados indicam que camundongosdas colônias e linhagens examinadas respondem de forma satisfatória e podem serutilizados como alternativas ao hibrido B6D2F1 no ensaio de potência de alfaepoetina. Os camundongos BALB/c, entretanto, foram os que responderam deforma mais semelhante aos híbridos B6D2F1 no ensaio de potência da EPOhr em termos dos coeficientes angulares e lineares da curva dose-resposta (curvas paralelas praticamente superpostas).Instituto Nacional de Controle de Qualidade em Saúde2013-08-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/8910.3395/vd.v1n3.89Health Surveillance under Debate: Society, Science & Technology ; Vol. 1 No. 3 (2013): August; 49 - 58Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 1 Núm. 3 (2013): Agosto; 49 - 58Vigil Sanit Debate, Rio de Janeiro; v. 1 n. 3 (2013): Agosto; 49 - 582317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89/60Copyright (c) 2013 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessSilva, Igor BarbosaMattos, Katherine AntunesDick, Paulo CesarAlmeida, Alessandra SantosSilva, Ricardo GonçalvesHokama, Darcy AkemiPaumgartten, Francisco José Roma2023-06-27T14:55:27Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/89Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T14:55:27Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
Ensaio de potência da alfaepoetina: Comparação de camundongos Swiss Webster, NIH, C57BL6, BALB/c com o híbrido B6D2F1
title Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
spellingShingle Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
Silva, Igor Barbosa
epoetin alpha
Potency assay
bioassay
mouse strains
human erythropoietin recombinant (rhEPO)
Alfaepoetina
ensaio de potência
bioensaio
linhagens de camundongos
eritropoietina recombiante humana (EPOhr)
title_short Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
title_full Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
title_fullStr Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
title_full_unstemmed Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
title_sort Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
author Silva, Igor Barbosa
author_facet Silva, Igor Barbosa
Mattos, Katherine Antunes
Dick, Paulo Cesar
Almeida, Alessandra Santos
Silva, Ricardo Gonçalves
Hokama, Darcy Akemi
Paumgartten, Francisco José Roma
author_role author
author2 Mattos, Katherine Antunes
Dick, Paulo Cesar
Almeida, Alessandra Santos
Silva, Ricardo Gonçalves
Hokama, Darcy Akemi
Paumgartten, Francisco José Roma
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Igor Barbosa
Mattos, Katherine Antunes
Dick, Paulo Cesar
Almeida, Alessandra Santos
Silva, Ricardo Gonçalves
Hokama, Darcy Akemi
Paumgartten, Francisco José Roma
dc.subject.por.fl_str_mv epoetin alpha
Potency assay
bioassay
mouse strains
human erythropoietin recombinant (rhEPO)
Alfaepoetina
ensaio de potência
bioensaio
linhagens de camundongos
eritropoietina recombiante humana (EPOhr)
topic epoetin alpha
Potency assay
bioassay
mouse strains
human erythropoietin recombinant (rhEPO)
Alfaepoetina
ensaio de potência
bioensaio
linhagens de camundongos
eritropoietina recombiante humana (EPOhr)
description In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves).
publishDate 2013
dc.date.none.fl_str_mv 2013-08-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
"Peer-reviewed article"
"Artículo revisado por pares"
"Artigo avaliado pelos pares"
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89
10.3395/vd.v1n3.89
url https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89
identifier_str_mv 10.3395/vd.v1n3.89
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89/60
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
dc.source.none.fl_str_mv Health Surveillance under Debate: Society, Science & Technology ; Vol. 1 No. 3 (2013): August; 49 - 58
Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 1 Núm. 3 (2013): Agosto; 49 - 58
Vigil Sanit Debate, Rio de Janeiro; v. 1 n. 3 (2013): Agosto; 49 - 58
2317-269X
reponame:Vigilância Sanitária em Debate
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Vigilância Sanitária em Debate
collection Vigilância Sanitária em Debate
repository.name.fl_str_mv Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br
_version_ 1797042043370864640